The binding profile of cyclazosin, a new prazosin-related alpha 1-adrenoceptor antagonist, at alpha 1-, alpha 2-adrenoceptors, dopamine D2 and 5-HT1A receptors was compared to that of 5-methylurapidil, spiperone, risperidone and other prazosin-related ligands. In addition, cyclazosin was investigated at native and cloned alpha 1-adrenoceptor subtypes. Cyclazosin showed high specificity for alpha 1-adrenoceptors and a 10-15-fold selectivity for alpha 1B (alpha 1b)-adrenoceptors with respect to the alpha 1A (alpha 1a) subtype (pKi values of 9.23-9.57 and 8.18-8.41, respectively). However, it failed to discriminate between cloned alpha 1b and alpha 1d-adrenoceptors (pKi values of 9.23 and 9.28, respectively).
Research. Development. Production.
We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.